---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-22-001463"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:35:39.162221+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports Q3 net income $1.4M on merger gain; NPM-119 on track for IND early 2023

## Summary
- Net income of $1.4M in Q3 2022 vs net loss of $3.5M in Q3 2021, driven by $6.9M bargain purchase gain from merger.
- Cash and equivalents $51.7M as of Sep 30, 2022; estimated to fund operations into second half of 2024.
- R&D expenses $3.9M (up 34% YoY); G&A $1.6M (up 167% YoY) due to higher headcount from merger.
- NPM-119 GLP-1 implant IND filing and LIBERATE-1 Phase 2 start expected early 2023; top-line results anticipated late 2023.

## SEC filing metadata
- accession: 0001753926-22-001463
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/0001753926-22-001463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/g083264_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-22-001463
- JSON: https://secwatch.observer/filing/0001753926-22-001463.json
- Plain text: https://secwatch.observer/filing/0001753926-22-001463.txt

## Key facts
- Earnings Releases
  Vivani Medical, Inc. reported the third quarter ended September 30, 2022 results: net income $1.4 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $1.4 million
  - Result: reported results
  source text: Net income was $1.4 million in the third quarter of 2022, compared to a net loss of $3.5 million in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392622001463/0001753926-22-001463-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.